Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week COPD study comparing budesonide + indacaterol versus fluticasone + salmeterol
RBR-6gphkrPhase 4Recruiting
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of budesonide, indacaterol, fluticasone and salmeterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Started Feb 2014; status: recruiting.
02
Drugs
budesonideindacaterolfluticasonesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on RBR-6gphkr.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6gphkr.